Intermediate results of efficacy and safety of combined treatment with brentuximab vedotin and bendamustine for refractory and relapsed forms of peripheral T-cell lymphoma: A retrospective study

Aim. To evaluate the efficacy and safety profile of the BvB combination in the treatment of R/R nPTCL, the complete response (CR) and partial response (PR) rates, overall survival (OS), and progression-free survival (PFS). Materials and methods. The analysis included 39 patients with R/R forms of nPTCL who underwent treatment in state budgetary institutions of the Moscow Department of Health (06.2008–08.2024). The efficacy (CR, PR, OS, PFS) and safety profile of the BvB combination were evaluated. Results. The best efficacy was noted when the BvB regimen was prescribed as a 2nd-line therapy compared to 3rd and subsequent lines. The overall response rate (ORR) when prescribed as 2nd-line therapy was 57% (n=13) of cases, CR – in 39.1% (n=9), PR – in 8.7% (n=2). The use of the BvB regimen as 3rd and subsequent lines of therapy led to ORR in 5 (31.3%) patients, CR – in 2 (12.5%), PR – in 2 (12.5%) patients. Statistically significant differences were obtained for the median PFS of patients who received the BvB regimen in the 2nd vs 3rd and subsequent lines of therapy: 6.5 and 2.5 months, respectively (p=0.0304). The BvB combination was characterized by an acceptable safety profile. Conclusion. The use of the BvB regimen in R/R forms of nPTCL demonstrated high efficacy and an optimal safety profile. The obtained results indicate the need to continue the study on a larger group of patients.